Beginning in 2017, numerous modifications to the guidelines have been and continue to be implemented to make guidelines shorter and enhance user friendli- ness. Guidelines are written and presented in a modu- lar knowledge chunk format, in which each chunk in- cludes a table of recommendations, a brief synopsis, recommendation-specific supportive text and, when appropriate, flow diagrams or additional tables. Hyper- linked references are provided for each modular knowl- edge chunk to facilitate quick access and review. More CLINICAL STATEMENTS AND GUIDELINES structured guidelines including word limits ( targets ) and a web guideline supplement for useful but non- critical tables and figures are 2 such changes. Also, to promote conciseness, the Preamble is presented in ab- breviated form in the executive summary and full-text guideline documents. In recognition of the importance of cost value con- siderations in certain guidelines, when appropriate and feasible, an analysis of value for a drug, device, or in- tervention may be performed in accordance with the To ensure that guideline recommendations remain current, new data are reviewed on an ongoing basis, with full guideline revisions commissioned ideally in ap- proximate 6-year cycles. Publication of potentially prac- tice-changing new study results relevant to an existing or new drug, device, or management strategy prompts evaluation by the Task Force, in consultation with the relevant guideline writing committee, to determine whether a focused update should be commissioned. 